Who Paid My Doc
A Phase 3A, Open-Label, Randomized, Controlled Study to Evaluate the I
Research payments
$232,693
Through program year 2025, $232,693 in research payments was reported against A Phase 3A, Open-Label, Randomized, Controlled Study to Evaluate the I, across 33 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $232,693 | 33 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Dmitriy Romanenko Tarzana, CA Named on 9 payments
- Ivo Alonso Coral Gables, FL Named on 5 payments
- Albert Nassir Los Angeles, CA Named on 5 payments
- Yvette Poindexter Alvin, TX Named on 4 payments
- Michele Johnson-Towson Tampa, FL Named on 3 payments
- Julie Shepard Dayton, OH Named on 3 payments
- Angel Rico Miami Lakes, FL Named on 1 payment
- Dena Petersen Tucson, AZ Named on 1 payment
- Jose Diaz Los Angeles, CA Named on 1 payment
- Thomas Turk Canyonville, OR Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.